JuliaHub doubling investment in the pharmaceutical sector
February 13, 2025JuliaHub is doubling its investment in the pharmaceutical sector, leveraging JuliaHub’s new-and-improved CFR Part 11-compliant pharmaceutical platform.
The company said that this latest release introduces advanced capabilities that further streamline workflows, improve compliance, and drive innovation across pharmacometrics, modeling, and analytics.
Deepak Vinchhi, Co-founder and COO of JuliaHub, emphasized the value of this partnership: “Our collaboration with Pumas-AI brings an unparalleled advantage in pharmaceutical development. By integrating advanced pharmacometric modeling with JuliaHub’s scalable, high-performance platform, we empower teams to achieve faster, more reliable outcomes – accelerating the delivery of life-saving treatments to patients. This partnership reflects a shared vision: to advance drug development through innovative, scalable, and compliant solutions that drive efficiency, accuracy, and groundbreaking discoveries across every stage of the pharmaceutical lifecycle.”
Vijay Ivaturi, CEO of Pumas-AI, talked about JuliaHub’s impact on pharmaceutical development: “Pumas-AI has successfully developed and submitted 26 drugs to the FDA using JuliaHub’s powerful platform. The scalability, performance, and compliance capabilities of JuliaHub have played a pivotal role in ensuring seamless drug development and regulatory success. JuliaHub is setting a new standard for efficiency and innovation in the pharmaceutical industry.”
